Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer

In total, 70 patients were enrolled into this phase II study, to evaluate the activity of the pegylated liposomal doxorubicin (PLD) and gemcitabine (GEM) combination in recurrent ovarian cancer patients. PLD, 30 mg m(−2), was administered on day 1 by 60′ i.v. infusion, followed by GEM, 1000 mg m(−2)...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Agostino, G, Ferrandina, G, Ludovisi, M, Testa, A, Lorusso, D, Gbaguidi, N, Breda, E, Mancuso, S, Scambia, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394291/
https://www.ncbi.nlm.nih.gov/pubmed/14520442
http://dx.doi.org/10.1038/sj.bjc.6601284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394291/
https://www.ncbi.nlm.nih.gov/pubmed/14520442
http://dx.doi.org/10.1038/sj.bjc.6601284

Ejemplares similares